Patents by Inventor Bradley Tait

Bradley Tait has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROTEOSTASIS REGULATORS
    Publication number: 20170247355
    Abstract: The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
    Type: Application
    Filed: January 10, 2017
    Publication date: August 31, 2017
    Inventors: Megan Foley, Bradley Tait, Matthew Cullen
  • Compounds, compositions, and methods for increasing CFTR activity
    Patent number: 9745292
    Abstract: The disclosure encompasses compounds having e.g., Formula (Ia) or (Ib), compositions thereof, and methods of modulating CFTR activity. The disclosure also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a compound of Formula (I) or (Ib).
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: August 29, 2017
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20170233379
    Abstract: The present disclosure features disclosed compounds which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.
    Type: Application
    Filed: June 19, 2015
    Publication date: August 17, 2017
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Proteostasis regulators
    Patent number: 9556166
    Abstract: The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
    Type: Grant
    Filed: May 10, 2012
    Date of Patent: January 31, 2017
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Megan Foley, Bradley Tait, Matthew Cullen
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20170001991
    Abstract: The disclosure encompasses compounds having e.g., Formula (Ia) or (Ib), compositions thereof, and methods of modulating CFTR activity. The disclosure also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a compound of Formula (I) or (Ib).
    Type: Application
    Filed: March 13, 2015
    Publication date: January 5, 2017
    Applicant: Proteostasis Therapeutics, Inc.
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    Publication number: 20170001993
    Abstract: The invention encompasses compounds such as compounds having the Formula (I) or (II), compositions thereof, and methods of modulating CFTR activity. The invention also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound.
    Type: Application
    Filed: March 13, 2015
    Publication date: January 5, 2017
    Inventors: Cecilia M. Bastos, Benito Munoz, Bradley Tait
  • Proteasome activity modulating compounds
    Patent number: 9399647
    Abstract: The present invention is directed to compounds having the Formula (I), (Ia) or (Ib), compositions thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: July 26, 2016
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Robert J. Chambers, Megan Foley, Bradley Tait
  • METHODS OF MODULATING CFTR ACTIVITY
    Publication number: 20160151335
    Abstract: The invention encompasses methods of modulating CFTR activity in a subject in need thereof comprising administering an effective amount of a compound of Formula (I). The invention also encompasses methods of treating a condition associated with CFTR activity or condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a compound of Formula (I).
    Type: Application
    Filed: June 25, 2014
    Publication date: June 2, 2016
    Applicant: Proteostasis Therapeutics, Inc.
    Inventors: Bradley Tait, Matthew Cullen
  • PROTEASOME ACTIVITY ENHANCING COMPOUNDS
    Publication number: 20150166567
    Abstract: The present invention is directed to compounds having the Formula (I), (Ia) or (Ib), compositions thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: July 17, 2014
    Publication date: June 18, 2015
    Inventors: Robert J. Chambers, Megan Foley, Bradley Tait
  • PROTEASOME ACTIVITY MODULATING COMPOUNDS
    Publication number: 20150166565
    Abstract: The present invention is directed to compounds having the Formula (I), (Ia) or (Ib), compositions thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Application
    Filed: July 17, 2014
    Publication date: June 18, 2015
    Inventors: Robert J. Chambers, Megan Foley, Bradley Tait
  • COMPOUNDS FOR TREATING PROTEIN FOLDING DISORDERS
    Publication number: 20130072473
    Abstract: The present invention is directed to compounds of Formulae (I), (IIa-IIh), (IIIa-IIIe), (IVa-IVc), (Va-V1), (VIa-VII), (VII), (VIII) and (IX), pharmaceutical compositions thereof and methods of use thereof in the treatment of conditions associated with a dysfunction in proteostasis.
    Type: Application
    Filed: May 9, 2012
    Publication date: March 21, 2013
    Inventors: Bradley Tait, Noel A. Powell, Matthew Cullen
  • PROTEOSTASIS REGULATORS
    Publication number: 20120316193
    Abstract: The present invention is directed to compounds having the Formulae (Ia-Ie), (II), (IIIa-IIId), (IVa-IVc), (Va-Vb), (VIa-VIe), (VII), (VIIIa-VIIIc), and (IX), pharmaceutically acceptable salts, prodrugs and solvates thereof, compositions of any of thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis comprising an effective amount of these compounds.
    Type: Application
    Filed: May 10, 2012
    Publication date: December 13, 2012
    Inventors: Megan Foley, Bradley Tait, Matthew Cullen
  • PROTEOSTASIS REGULATORS
    Publication number: 20120214824
    Abstract: The present invention is directed to compounds of Formulae (I), (II), (III), (IV), (V), (VI), (VII), and (VIII), pharmaceutical compositions thereof and methods of use thereof in the treatment of conditions associated with a dysfunction in proteostasis.
    Type: Application
    Filed: December 8, 2011
    Publication date: August 23, 2012
    Inventors: Bradley Tait, Christopher Borella, Robert Chambers, Matthew Cullen
  • HIV protease inhibitors
    Publication number: 20050075390
    Abstract: The present invention relates to novel dihydropyrones with tethered heterocycles having improved pharmacologic properties which potently inhibit the HIV aspartyl protease blocking HIV infectivity. The dihydropyrones are useful in the development of therapies for the treatment of viral infections and diseases, including AIDS. The present invention is also directed to methods of synthesis of the dihydropyrones and intermediates useful in the preparation of the final compounds.
    Type: Application
    Filed: September 9, 2004
    Publication date: April 7, 2005
    Inventors: Frederick Boyer, John Domagala, Edmund Ellsworth, Christopher Gajda, Susan Hagen, Michael Lovdahl, Elizabeth Lunney, Larry Markoski, Josyula Venkata Prasad, Bradley Tait
  • Inhibitors of acyl-coenzyme A: cholesterol acyl transferase
    Patent number: 5326762
    Abstract: Amides of the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently heteroaryl, X-substituted heteroaryl, X-substituted phenyl, N-substituted triazinyl or N-substituted imidazolyl;and in addition, one of R.sub.1 and R.sub.2 can be as defined above and the other can be phenyl;R.sub.3 is an alkyl chain of 2 to 25 carbon atoms, saturated or unsaturated; an alkyl chain as defined substituted by one or more substituents selected from the group consisting of phenyl, X-substituted phenyl, heteroaryl and X-substituted heteroaryl; an alkyl chain as defined interrupted by one or more groups independently selected from the group consisting of --O--, --S--, --SO--, --SO.sub.2 --, --NH--, --N(lower alkyl)--, --C(O)--, phenylene, X-substituted phenylene, heteroarylene and X-substituted heteroarylene; or an interrupted alkyl chain as defined substituted by one or more substituents selected form the group consisting of phenyl, X-substituted phenyl, heteroaryl and X-substituted heteroaryl;R.sub.
    Type: Grant
    Filed: May 19, 1992
    Date of Patent: July 5, 1994
    Assignee: Schering Corporation
    Inventors: John Clader, Sundeep Dugar, Timothy Kogan, Bradley Tait, Wayne Vaccaro
  • Inhibitors of acyl-coenzyme A: cholesterol acyl transferase
    Patent number: 5149709
    Abstract: Amides of the formula ##STR1## wherein R.sub.1 and R.sub.2 are independently heteroaryl, X-substituted heteroaryl, X-substituted phenyl, N-substituted triazinyl or N-substituted imidazolyl;and in addition, one of R.sub.1 and R.sub.2 can be as defined above and the other can be phenyl;R.sub.3 is an alkyl chain of 2 to 25 carbon atoms, saturated or unsaturated; an alkyl chain as defined substituted by one or more substituents selected from the group consisting of phenyl, X-substituted phenyl, heteroaryl and X-substituted heteroaryl; an alkyl chain as defined interrupted by one or more groups independently selected from the group consisting of --O--, --S--, --SO--, --SO.sub.2 --, --NH--, --N(lower alkyl)--, --C(O)--, phenylene, X-substituted phenylene, heteroarylene and X-substituted heteroarylene; or an interrupted alkyl chain as defined substituted by one or more substituents selected from the group consisting of phenyl, X-substituted phenyl, heteroaryl and X-substituted heteroaryl;R.sub.
    Type: Grant
    Filed: July 3, 1990
    Date of Patent: September 22, 1992
    Assignee: Schering Corporation
    Inventors: John Clader, Sundeep Dugar, Timothy Kogan, Bradley Tait, Wayne Vaccaro